SenzaGen granted its first patent for GARD™potency
SenzaGen's patent application that protects the biomarker signature to measure how strongly allergenic a substance is, has now been granted in Europe. The patent is SenzaGen's first patent in the area of potency classification. The patent's validity extends to 2036.The technology of SenzaGen's patent is implemented in the company's testing application, which for the first time makes it possible to measure the allergenicity of chemical substances, so-called potency classification, without animal research. “Getting this patent on the European market is commercially